Navigation Links
Concomitant treatment with nebulized formoterol fumarate & tio-significant improvements -- COPD
Date:5/20/2008

Napa, CA, (May 20, 2008) A newly published study presents data demonstrating that patients with Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, experienced markedly improved bronchodilation and symptom control when treated with a combination of nebulized formoterol fumarate inhalation solution (Perforomist Inhalation Solution) and tiotropium (TIO), compared to treatment with tiotropium alone. The two medications, when used adjunctively, were also well tolerated by patients over the course of the 6-week study.

Concomitant Treatment with Nebulized Formoterol and Tiotropium in Subjects with COPD: A Placebo-Controlled Trial, published in Respiratory Medicine, assesses the efficacy and safety of the concomitant treatment of Perforomist nebulized formoterol fumarate (a long-acting β-agonist [LABA]) and tiotropium (an anticholinergic) in 130 adults with moderate to severe COPD.

These data provide additional insight into the additive benefit of concomitant therapy with a LABA and a long-acting anticholinergic, said Dr. Donald Tashkin, MD, FACP, FCCP, Professor of Medicine, David Geffen School of Medicine at the University of California at Los Angeles, lead author and principal investigator of the study. When Perforomist Solutions rapid onset of action is combined with tiotropiums prolonged bronchodilation, the result appears to be a safe and effective treatment option for patients. This is great news for the millions of patients and their families -- who live with COPD, and who too often struggle with an insufficient number of robust treatment options.

About the Study

The study was a six-week, randomized, double-blind, placebo-controlled, parallel-group design study. COPD patients entered a 7-14 day run-in period during which subjects received once-daily treatment with tiotropium bromide inhalation powder (TIO; Spiriva, 18 g) administered with a HandiHaler. Following randomization, subjects entered a six-week treatment period to evaluate the safety and efficacy of formoterol fumarate inhalation solution (FFIS; Perforomist, 20 g/2mL) while maintaining once-daily treatment with TIO. The primary efficacy endpoint was standardized area under the curve for FEV1 over three hours (FEV1 AUC0-3) at the last visit (week 6).

The standardized absolute AUC0-3 for FEV1 following the first dose of study medication at Day 1 was statistically significantly improved in the Perforomist/TIO group compared with placebo/TIO group (PLA/TIO). FEV1 AUC0-3 remained significantly greater in the Perforomist/TIO group after six weeks without any decrease of effect or evidence of tolerance (p< 0.0001). Peak FEV1 levels were significantly higher in the Perforomist/TIO group compared with PLA/TIO (p< 0.0001). Symptoms, including shortness of breath, chest tightness, night-time awakenings, and the total respiratory symptom score, were all significantly improved in the Perforomist/TIO group compared with PLA/TIO. Use of albuterol rescue medication declined in the Perforomist/TIO group and remained low throughout the treatment, whereas albuterol use in the PLA/TIO group trended higher through the six weeks of treatment (p<0.0001), suggesting enhanced control of COPD symptoms.

Quality of life was assessed with St. Georges Respiratory Questionnaire (SGRQ), the results of which were similar at day 1 and did not change markedly over the six weeks of treatment. The only statistically significant and clinically relevant treatment difference observed with Perforomist/TIO compared with PLA/TIO was an improvement in symptom score (LS mean change of -5.8 units).

Other Recently Published Data

Results from the Phase III pivotal trial of Perforomist (formoterol fumarate) Inhalation Solution, the first and only FDA-approved nebulized formoterol fumarate, were also recently published. Perforomist Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of COPD.

  • Efficacy and Safety of Formoterol Fumarate Delivered by Nebulization to COPD Patients, published in the February 2008 issue of Respiratory Medicine, detailed pivotal Phase III data that supported the NDA approval for Perforomist (formoterol fumarate) Inhalation Solution. The study demonstrated that Perforomist Inhalation Solution has a rapid onset of significant bronchodilation within five minutes of administration and is safe and effective. The study assessed the efficacy and safety of Perforomist Inhalation Solution in 351 adults with moderate-to-severe COPD. Nicholas J. Gross, MD, PhD, Hines VA Hospital, Stricht Loyola School of Medicine, was lead author and principal investigator of the study.

  • In October 2007, Clinical Therapeutics published cardiac safety results from the Phase III trial for Perforomist Inhalation Solution. In Cardiac Safety Profile of Nebulized Formoterol in Adults with COPD: A 12-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled Trial, the data showed that Perforomist Inhalation Solution was associated with rapid and sustained improvement in pulmonary function with no clinically significant cardiac effects, including QT prolongation, increased proarrhythmic events, or changes in serum potassium levels. Harold S. Nelson, MD, Professor of Medicine, National Jewish Medical and Research Center; was lead author of the article and principal investigator of the study. Patients with cardiac problems were excluded from the study. Perforomist should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrythmias, and hypertension.

Funding for these studies was provided by Dey, L.P., manufacturer and marketer of Perforomist (formoterol fumarate) Inhalation Solution. Perforomist Inhalation Solution is the first and only FDA-approved nebulized form of formoterol fumarate. Formoterol fumarate is a rapid and long-acting beta2-agonist (LABA) that has been previously available in the U.S. in a dry powder formulation with twenty years of worldwide experience. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or facemask.

Taken together, these studies expand our understanding of the clinical benefits of Perforomist Inhalation Solution for the treatment of COPD, said Carolyn Myers, Ph.D., President of Dey, L.P. Perforomist Inhalation Solution offers physicians a flexible, safe, and highly effective treatment option for COPD -- and many patients may benefit from this new addition to the treatment armamentarium.


'/>"/>

Contact: Amy Techtmann
amy.techtmann@fkhealth.com
617-761-6784
Feinstein Kean Healthcare
Source:Eurekalert

Related medicine news :

1. Clinical trial data: Safety/efficacy of concomitant formoterol fumarate/tiotropium treating COPD
2. New treatment effective in counteracting cocaine-induced symptoms
3. New treatment boosts muscle function in myasthenia gravis
4. Broad-based group of physicians calls for improvement in stroke treatment
5. Cranberry Could Juice Up Ovarian Cancer Treatment
6. Non-medicinal treatment touted for pre-schoolers with ADHD
7. Nonmedicinal treatment touted for preschoolers with ADHD
8. U of M study: Early treatment can reverse heart damage
9. Biologic treatment for rheumatoid arthritis and the risk of cancer
10. New Treatment Explored for Cluster Headaches
11. Thailand: Partners Open Free AIDS Treatment Clinic in Renowned AIDS Temple in Lop Buri
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology: